The global Viral Clearancemarket was valued at USD 320.18million in 2016 and is projected to reach USD 902.98billionby 2025, growing at a CAGR of 12.21% from 2017 to 2025.
The prevalence of chronic viral infections and diseases is increasing generating demand for efficient diagnostics and treatment methods. The market is thus expected to grow at a high CAGR.
Sample Infographics:
Market Dynamics:
1. Market Drivers
1.1 Rapid Growth in Pharmaceutical and Biotechnology Industries
1.2 Increasing Number of New Drug Launches
1.3 Strong Trend of R&D Investments in the Life Sciences Industry
1.4 Increasing Government Support for Pharmaceutical and Biotechnology Industries
1.5 High Incidence and Large Economic Burden of Chronic Diseases
2. Market Restraints
2.1 High Degree of Consolidation to Act as A Major Barrier for New Entrants
Market Segmentation:
1. By Method:
1.1 Viral Detection Method
1.1.1 Plaque Assays
1.1.2 Pcr
1.1.3 Elisa
1.1.4 Other Viral Detection Methods
1.2 Viral Removal
1.2.1 Chromatography
1.2.2 Nanofiltration
1.2.3 Precipitation
1.3 Viral Inactivation
1.3.1 Solvent Detergent Method
1.3.2 Pasteurization
1.3.3 Other Methods
2. By End User:
2.1 Pharmaceutical and Biotechnology Companies
2.2 Contract Research Organizations
2.3 Academic Research Institutes
2.4 Other End Users
3. By Application:
3.1 Vaccines and Therapeutics
3.2 Blood and Blood Products
3.3 Cellular and Gene Therapy Products
3.4 Tissue and Tissue Products
3.5 Stem Cell Products
4. By Region:
4.1 North America (U.S., Canada, Mexico)
4.2 Europe (Germany, UK, France, Rest of Europe)
4.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
4.4 Latin America (Brazil, Argentina, Rest of Latin America)
4.5 Middle East & Africa
Competitive Landscape:
The major players in the market are as follows:
1. Charles River Laboratories International, Inc.
2. Lonza Group
3. Sigma-Aldrich Corporation
4. SGS S.A.
5. Wuxi Pharmatech (Cayman) Inc.
6. Avance Biosciences Inc.
7. BSL Bioservice
8. Clean Cells Inc.
9. Merck KGAA
10. Texcell, Inc.
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Viral Clearancemarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
1 INTRODUCTION OF GLOBAL VIRAL CLEARANCEMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL VIRAL CLEARANCEMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL VIRAL CLEARANCE MARKET, BY METHOD
5.1 Viral Detection Method
5.1.1 Plaque Assays
5.1.2 Pcr
5.1.3 Elisa
5.1.4 Other Viral Detection Methods
5.2 Viral Removal
5.2.1 Chromatography
5.2.2 Nanofiltration
5.2.3 Precipitation
5.3 Viral Inactivation
5.3.1 Solvent Detergent Method
5.3.2 Pasteurization
5.3.3 Other Methods
6 GLOBAL VIRAL CLEARANCE MARKET, BY END USER
6.1 Pharmaceutical and Biotechnology Companies
6.2 Contract Research Organizations
6.3 Academic Research Institutes
6.4 Other End Users
7 GLOBAL VIRAL CLEARANCE MARKET, BY APPLICATION
7.1 Vaccines and Therapeutics
7.2 Blood and Blood Products
7.3 Cellular and Gene Therapy Products
7.4 Tissue and Tissue Products
7.5 Stem Cell Products
8 GLOBAL VIRAL CLEARANCEMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025
9 GLOBAL VIRAL CLEARANCEMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies
10 COMPANY PROFILES
10.1 Charles River Laboratories International, Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
10.2 Lonza Group
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments
10.3 Sigma-Aldrich Corporation
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments
10.4 SGS S.A.
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments
10.5 Wuxi Pharmatech (Cayman) Inc.
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments
10.6 Avance Biosciences Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments
10.7 BSL Bioservice
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments
10.8 Clean Cells Inc.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments
10.9 Merck KGAA
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Development
10.10 Texcell, Inc.
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Development
11 Appendix
11.1 Related Reports